Which oral diuretic regimen is approximately equipotent to intravenous furosemide 40 mg twice daily?

Which oral diuretic regimen is approximately equipotent to intravenous furosemide 40 mg twice daily?

• A. Bumetanide 4 mg by mouth twice daily
• B. Torsemide 40 mg by mouth once daily
• C. Furosemide 40 mg by mouth twice daily
• D. Metolazone 5 mg by mouth twice daily

Answer: (B)

The correct answer is that an oral regimen of torsemide 40 mg taken once daily is approximately equipotent to intravenous furosemide 40 mg administered twice daily. This equivalence is based on the pharmacokinetic properties and relative potency of diuretics within the loop diuretic class. Furosemide and torsemide are both loop diuretics, but they differ in their bioavailability and potency. Furosemide is approximately 50% bioavailable when taken orally. In contrast, torsemide has higher bioavailability (about 80-100%) and a longer half-life, which allows for once-daily dosing to achieve similar effects compared to furosemide, particularly in acute or chronic heart failure settings. The dosing of torsemide is adjusted to accommodate its greater potency, equating approximately to the intravenous furosemide dosage for optimal diuretic effect. Hence, the oral torsemide regimen mentioned aligns with the goal of achieving a diuretic response similar to that provided by intravenous furosemide, notably in patients requiring continuous diuretic therapy. Other options do not provide the same equivalence. For example, bumetanide, while also a loop diuretic,

The correct answer is that an oral regimen of torsemide 40 mg taken once daily is approximately equipotent to intravenous furosemide 40 mg administered twice daily. This equivalence is based on the pharmacokinetic properties and relative potency of diuretics within the loop diuretic class.

Furosemide and torsemide are both loop diuretics, but they differ in their bioavailability and potency. Furosemide is approximately 50% bioavailable when taken orally. In contrast, torsemide has higher bioavailability (about 80-100%) and a longer half-life, which allows for once-daily dosing to achieve similar effects compared to furosemide, particularly in acute or chronic heart failure settings.

The dosing of torsemide is adjusted to accommodate its greater potency, equating approximately to the intravenous furosemide dosage for optimal diuretic effect. Hence, the oral torsemide regimen mentioned aligns with the goal of achieving a diuretic response similar to that provided by intravenous furosemide, notably in patients requiring continuous diuretic therapy.

Other options do not provide the same equivalence. For example, bumetanide, while also a loop diuretic,